文献速递泌尿生殖妇产影像PETCT

FDG PET/CT识别宫颈癌和子宫内膜癌远处转移:ACRIN 6671/GOG 0233多中心试验分析

Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial.
PubMed 文献 · Radiology · 2017-11-29

该前瞻性多中心试验纳入153例宫颈癌和203例子宫内膜癌患者,评估FDG PET/CT检测远处转移的准确性,并比较中心审阅与机构即时判读的效能差异。中心审阅的灵敏度和特异度分别为宫颈癌54.8%和97.7%、子宫内膜癌64.6%和98.6%;中心审阅的特异度和阳性预测值显著高于机构判读,AUC值两者无显著差异。结论认为FDG PET/CT对宫颈癌和子宫内膜癌远处转移具有高特异度和阳性预测值,应纳入分期评估。

要点

  • FDG PET/CT对宫颈癌和子宫内膜癌远处转移具有高特异度和阳性预测值,原文认为应纳入分期评估。
  • 中心审阅的特异度和阳性预测值均显著高于机构即时判读(P < .05)。
  • 中心审阅与机构判读的AUC值无显著差异(宫颈癌0.78 vs 0.75,子宫内膜癌0.89 vs 0.84,P均> .05)。

核心结论

  • FDG PET/CT对宫颈癌和子宫内膜癌远处转移具有高特异度和阳性预测值,原文认为应纳入分期评估。
  • 对影像进行盲法中心审阅可提高检测转移的特异度和阳性预测值,原文认为可考虑用于未来肿瘤影像临床试验。

研究设计与样本

  • 前瞻性多中心试验(ACRIN 6671/GOG 0233),纳入153例宫颈癌和203例子宫内膜癌患者,来自28个中心。
  • 两名中心审阅者在不知晓机构判读和参考标准的情况下审阅PET/CT图像判断远处转移,并与机构即时判读比较。
  • 参考标准为病理和影像随访。

诊断标准与关键数值

  • 中心审阅PET/CT检测宫颈癌远处转移的敏感度54.8%、特异度97.7%、阳性预测值79.3%、阴性预测值93.1%。
  • 中心审阅PET/CT检测子宫内膜癌远处转移的敏感度64.6%、特异度98.6%、阳性预测值86.1%、阴性预测值95.4%。
  • 机构判读检测宫颈癌远处转移的敏感度47.6%、特异度93.9%、阳性预测值55.6%、阴性预测值91.9%。
  • 机构判读检测子宫内膜癌远处转移的敏感度66.7%、特异度93.9%、阳性预测值59.3%、阴性预测值95.5%。
  • 中心审阅AUC:宫颈癌0.78、子宫内膜癌0.89;机构判读AUC:宫颈癌0.75、子宫内膜癌0.84;两者均无显著差异(P > .05)。

临床应用与阅片要点

  • 原文结论认为FDG PET/CT应纳入宫颈癌和子宫内膜癌的分期评估。
  • 原文结论认为盲法中心审阅可考虑用于未来肿瘤影像临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To assess the accuracy of staging positron emission tomography (PET)/computed tomography (CT) in detecting distant metastasis in patients with local-regionally advanced cervical and high-risk endometrial cancer in the clinical trial by the American College of Radiology Imaging Network (ACRIN) and the Gynecology Oncology Group (GOG) (ACRIN 6671/GOG 0233) and to compare central and institutional reader performance. Materials and Methods In this prospective multicenter trial, PET/CT and clinical data were reviewed for patients enrolled in ACRIN 6671/GOG 0233. Two central readers, blinded to site read and reference standard, reviewed PET/CT images for distant metastasis. Central review was then compared with institutional point-of-care interpretation. Reference standard was pathologic and imaging follow-up. Test performance for central and site reviews of PET/CT images was calculated and receiver operating characteristic analysis was performed. Generalized estimating equations and nonparametric bootstrap procedure for clustered data were used to assess statistical significance. Results There were 153 patients with cervical cancer and 203 patients with endometrial cancer enrolled at 28 sites. Overall prevalence of distant metastasis was 13.7% (21 of 153) for cervical cancer and 11.8% (24 of 203) for endometrial cancer. Central reader PET/CT interpretation demonstrated sensitivity, specificity, positive predictive value (PPV), and negative predictive value of 54.8%, 97.7%, 79.3%, and 93.1% for cervical cancer metastasis versus 64.6%, 98.6%, 86.1%, and 95.4% for endometrial cancer, respectively. By comparison, local institutional review demonstrated sensitivity, specificity, PPV, and negative predictive value of 47.6%, 93.9%, 55.6%, and 91.9% for cervical cancer metastasis and 66.7%, 93.9%, 59.3%, and 95.5% for endometrial cancer, respectively. For central readers, the specificity and PPV of PET/CT detection of cervical and endometrial cancer metastases were all significantly higher compared with that of local institutional review (P < .05). Central reader area under the receiver operating characteristic curve (AUC) values were 0.78 and 0.89 for cervical and endometrial cancer, respectively; these were not significantly different from local institutional AUC values (0.75 and 0.84, respectively; P > .05 for both). Conclusion FDG PET/CT demonstrates high specificity and PPV for detecting distant metastasis in cervical and endometrial cancer and should be included in the staging evaluation. Blinded central review of imaging provides improved specificity and PPV for the detection of metastases and should be considered for future oncologic imaging clinical trials. © RSNA, 2017.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Gee MS, Atri M, Bandos AI, et al. Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology. 2017. PMID: 29185901. doi:10.1148/radiol.2017170963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。